Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Emuliquen (often misspelled as Emoliquen) is a laxative product developed and marketed by the Spanish pharmaceutical company LAINCO S.A. It is primarily available in two formulations: Emuliquen Laxante, which is a combination of liquid paraffin and sodium picosulfate, and Emuliquen Simple, which contains only liquid paraffin. Liquid paraffin acts as a lubricant laxative by softening the stool and coating the intestinal wall to facilitate passage. Sodium picosulfate is a stimulant laxative that is metabolized by colonic bacteria into an active metabolite that stimulates the enteric nervous system to increase peristalsis. Emuliquen is indicated for the symptomatic relief of occasional constipation, particularly in patients with hemorrhoids, anal fissures, or other painful conditions of the anus and rectum where straining should be avoided. A Phase IV clinical trial (NCT01154101) has evaluated its efficacy in improving patient comfort and reducing defecation effort in adults following proctological surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on liquid paraffin + sodium picosulfate.